Integrating Continuous and Single-Use Methods to Establish a New Downstream Processing Platform for Monoclonal Antibodies

Continuous Processing in Pharmaceutical Manufacturing

Volumn , Issue , 2015, Pages 71-96

  Gillespie, Christopher ^a   Kozlov, Mikhail ^a   Phillips, Michael ^a   Potty, Ajish ^a   Skudas, Romas ^b   Stone, Matthew ^a   Xenopoulos, Alex ^a   Dupont, Alison ^a   Jaber, Jad ^a   Cataldo, William ^a  

^a EMD Millipore   (United States)

^b MERCK KGAA   (Germany)

Author keywords

Downstream purification process (DSP); Monoclonal antibodies (mAbs)

Indexed keywords

PURIFICATION; SURFACE PLASMON RESONANCE; VIRUSES;

BASIC CONCEPTS; CASE-STUDIES; CONTINUOUS PROCESS; DOWNSTREAM PURIFICATIONS; DOWNSTREAM-PROCESSING; MONOCLONAL ANTIBODIES (MABS); PROCESS DEVELOPMENT; PURIFICATION PROCESS;

MONOCLONAL ANTIBODIES;

EID: 84948994960     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527673681.ch04     Document Type: Chapter

References (75)

1. Leavy, O. (2010) Therapeutic antibodies:past, present and future. Nat. Rev. Immunol., 10 (5), 297-297.
2. Shukla, A.A. and Thömmes, J. (2010) Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends Biotechnol., 28 (5), 253-26. 1
3. Aggarwal, S. (2011) What's fueling the biotech engine: 2010 to 2011. Nat. Biotechnol., 29 (12), 1083-1089.
4. Jain, E. and Kumar, A. (2008) Upstream processes in antibody production:evaluation of critical parameters. Biotechnol. Adv., 26 (1), 46-72.
5. De Palma, A. (2013) Downstream process bottlenecks. GEN, 33 (13), 1, 36. doi: 10.1089/gen.33.13.17.
6. Langer, E. (2013) Keeping new technologies coming. BioPharm. Int., 11 (6), 12-15.
7. Sommerfeld, S. and Strube, J. (2005) Challenges in biotechnology production:generic processes and process optimization for monoclonal antibodies. Chem. Eng. Process: Process Intensification, 44 (10), 1123-1137.
8. Wurm, F.M. (2004) Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol., 22 (11), 1393-1398.
9. DePalma, A. (2011) Getting around downstream bottlenecks. GEN, 31 (11), 1-36.
10. Zaman, F., Allan, C.M., and Ho, S.V. (2009) Ultra scale-down approaches for clarification of mammalian cell culture broths in disc-stack centrifuges. Biotechnol. Prog., 25 (6), 1709-1716.
11. Westoby, M., Rogers, J.K., Haverstock, R., Romero, J., and Pieracci, J. (2011) Modeling industrial centrifugation of mammalian cell culture using a capillary based scale-down system. Biotechnol. Bioeng., 108 (5), 989-998.
12. Liu, H.F., Ma, J., Winter, C., and Bayer, R. (2010) Recovery and purification process development for monoclonal antibody production. mAbs, 2 (5), 480-499.
13. Lutz, H., Blanchard, M., Abbott, I., Parampalli, A., Setiabudi, G., Chiruvolu, V., and Noguchi, M. (2009) Considerations for scaling-up depth filtration of harvested cell culture fluid. BioPharm. Int., 22 (3), 58-66.
14. Belter, P.A., Cussler, E.L., and Hu, W.S. (1988) Bioseparations: Downstream Processing for Biotechnology, John Wiley & Sons, Inc., Hoboken.
15. Shukla, A.A. and Kandula, J.R. (2008) Harvest and recovery of monoclonal antibodies from large-scale mammalian cell culture. BioPharm. Int., 21 (5), 34-45.
16. Shpritzer, R., Vicik, S., Orlando, S., Acharya, H., and Coffman, J.L. (2006) Calcium phosphate flocculation of antibody-producing mammalian cells at pilot scale. The 232nd ACS National Meeting, September 10-14, 2006, San Francisco, CA, p. BIOT-80.
17. Roush, D.J. and Lu, Y. (2008) Advances in primary recovery: centrifugation and membrane technology. Biotechnol. Prog., 24 (3), 488-495.
18. Filipowicz, M. and Filipowicz, P. (1980) Continuous filtering-settling centrifuge. US Pat. 4199459A (April 22, 1980).
19. Tokashiki, M., Arai, T., Hamamoto, K., and Ishimaru, K. (1990) High density culture of hybridoma cells using a perfusion culture vessel with an external centrifuge. Cytotechnology, 3 (3), 239-244.
20. Pattasseril, J., Varadaraju, H., Lock, L., and Rowley, J. (2013) Downstream technology landscape for large-scale therapeutic cell processing. Bioprocess Int., 11, 46-52.
21. Yigzaw, Y., Piper, R., Tran, M., and Shukla, A.A. (2006) Exploitation of the adsorptive properties of depth filters for host cell protein removal during monoclonal antibody purification. Biotechnol. Prog., 22 (1), 288-296.
22. Eschrich, J., Cyr, G., and Dorsey, N. (1997) The role of charge in the retention of DNA by charged cellulose-based depth filters. BioPharm. Technol. Bus., 10 (1), 46-49.
23. Hou, K., Gerba, C., Goyal, S., and Zerda, K. (1980) Capture of latex beads, bacteria, endotoxin, and viruses by charge-modified filters. Appl. Environ. Microbiol., 40 (5), 892-896.
24. van Reis, R. and Zydney, A. (2001) Membrane separations in biotechnology. Curr. Opin. Biotechnol., 12 (2), 208-211.
25. Rossignol, N., Vandanjon, L., Jaouen, P., and Quemeneur, F. (1999) Membrane technology for the continuous separation microalgae/culture medium: compared performances of cross-flow microfiltration and ultrafiltration. Aquacult. Eng., 20 (3), 191-208.
26. Crespo, J., Xavier, A., Barreto, M., Goncalves, L., Almeida, J., and Carrondo, M. (1992) Tangential flow filtration for continuous cell recycle culture of acidogenic bacteria. Chem. Eng. Sci., 47 (1), 205-214.
27. Vaks, B., Mory, Y., Pederson, J., and Horovitz, O. (1984) A semi-continuous process for the production of human interferon-αc from E. coli using tangentialflow microfiltration and immuno-affinity chromatography. Biotechnol. Lett., 6 (10), 621-626.
28. Jungbauer, A. (2013) Continuous downstream processing of biopharmaceuticals. Trends Biotechnol., 31 (8), 479-492.
29. Dizon-Maspat, J., Bourret, J., D'Agostini, A., and Li, F. (2012) Single pass tangential flow filtration to debottleneck downstream processing for therapeutic antibody production. Biotechnol. Bioeng., 109 (4), 962-970.
30. Teske, C.A., Lebreton, B., and Reis, R.V. (2010) Inline ultrafiltration. Biotechnol. Prog., 26 (4), 1068-1072.
31. Bolto, B. and Gregory, J. (2007) Organic polyelectrolytes in water treatment. Water Res., 41 (11), 2301-2324.
32. Riske, F., Schroeder, J., Belliveau, J., Kang, X., Kutzko, J., and Menon, M.K. (2007) The use of chitosan as a flocculant in mammalian cell culture dramatically improves clarification throughput without adversely impacting monoclonal antibody recovery. J. Biotechnol., 128 (4), 813-823.
33. Romero, J., Chrostowski, J., De Vilmorin, P.G., and Case, J.Y. (2007) Method of isolating biomacromolecules using low pH and divalent cations. US Pat. 20100145022 A1 (November 1, 2007).
34. Kang, Y.K., Hamzik, J., Felo, M., Qi, B., Lee, J., Ng, S., Liebisch, G., Shanehsaz, B., Singh, N., and Persaud, K. (2013) Development of a novel and efficient cell culture flocculation process using a stimulus responsive polymer to streamline antibody purification processes. Biotechnol. Bioeng., 110 (11), 2928-2937.
35. Lydersen, B.K., Brehm-Gibson, T., and Murel, A. (1994) Acid precipitation of mammalian cell fermentation broth. Ann. N. Y. Acad. Sci., 745 (1), 222-231.
36. Sjöquist, J., Movitz, J., Johansson, I.-B., and Hjelm, H. (1972) Localization of protein A in the bacteria. Eur. J. Biochem., 30 (1), 190-194.
37. Hjelm, H. (1975) Isolation of IgG3 from normal human sera and from a patient with multiple myeloma by using protein A-Sepharose 4B. Scand. J. Immunol., 4 (6), 633-640.
38. Kronvall, G., Quie, P.G., and Williams, R.C. (1970) Quantitation of staphylococcal protein A: determination of equilibrium constant and number of protein A residues on bacteria. J. Immunol., 104 (2), 273-278.
39. Lain, B. (2013) Protein A: the life of a disruptive technology. Bioprocess Int., 11, 8.
40. Arunakumari, A., Wang, J.M., and Ferreira, G. (2007) Alternatives to protein A: improved downstream process design for human monoclonal antibody production. Biopharm International.
41. Thommes, J. and Etzel, M. (2007) Alternatives to chromatographic separations. Biotechnol. Prog., 23 (1), 42-45.
42. Ghose, S., Hubbard, B., and Cramer, S.M. (2006) Evaluation and comparison of alternatives to protein A chromatography mimetic and hydrophobic charge induction chromatographic stationary phases. J. Chromatogr. A, 1122 (1-2), 144-152.
43. Shinkazh, O., Kanani, D., Barth, M., Long, M., Hussain, D., and Zydney, A.L. (2011) Countercurrent tangential chromatography for large-scale protein purification. Biotechnol. Bioeng., 108 (3), 582-591.
44. Napadensky, B., Shinkazh, O., Teella, A., and Zydney, A.L. (2013) Continuous countercurrent tangential chromatography for monoclonal antibody purification. Sep. Sci. Technol., 48 (9), 1289-1297.
45. Broughton, C.B. and Gerhold, C.G. (1961) US Pat. 2,985,589.
46. Sá Gomes, P. and Rodrigues, A.E. (2012) Simulated moving bed chromatography:from concept to proof-of-concept. Chem. Eng. Technol., 35 (1), 17-34.
47. Strube, J., Altenhöner, U., Meurer, M., and Schmidt-Traub, H. (1997) Optimierung kontinuierlicher simulated-moving-bedchromatographie-prozesse durch dynamische simulation. Chem. Ing. Tech., 69 (3), 328-331.
48. Seidel-Morgenstern, A., Keßler, L.C., and Kaspereit, M. (2008) Neue entwicklungen auf dem gebiet der simulierten gegenstromchromatographie. Chem. Ing. Tech., 80 (6), 725-740.
49. Mueller-Spaeth, T., Angarita, M., Baur, D., Lievrouw, R., Lissens, G., Stroehlein, G., Bavand, M., and Morbidelli, M. (2013) Increasing capacity utilization in protein A chromatography. BioPharm. Int., 26 (10), 33-38.
50. Andersson, J. and Mattiasson, B. (2006) Simulated moving bed technology with a simplified approach for protein purification: separation of lactoperoxidase and lactoferrin from whey protein concentrate. J. Chromatogr. A, 1107 (1-2), 88-95.
51. Pollock, J., Bolton, G., Coffman, J., Ho, S.V., Bracewell, D.G., and Farid, S.S. (2013) Optimising the design and operation of semi-continuous affinity chromatography for clinical and commercial manufacture. J. Chromatogr. A, 1284, 17-27.
52. Mahajan, E., George, A., and Wolk, B. (2012) Improving affinity chromatography resin efficiency using semi-continuous chromatography. J. Chromatogr. A, 1227, 154-162.
53. Gillespie, C., Phillips, M., Mann, F., and Andrecht, S. (2013) Next-generation downstream template for continuous mAb processing. Continuous Processing in Biopharmaceutical Manufacturing, July 1-2, 2013, Cambridge, UK.
54. Nanying Bian, C.G., Stone, M., Kozlov, M., Chen, J., and Siwak, M. (2013) Methods of reducing level of one of more impurities in a sample during protein purification. EMD Millipore Corporation. Patent WO2013028330.
55. Marsh, H. and Rodríguez-Reinoso, F. (2006) Activated Carbon, Elsevier Science Ltd, Oxford.
56. Kopper, R.A., Kim, A., Van, T., and Helm, R.M. (2008) Adsorption of peanut (Arachis hypogaea, Leguminosae) proteins by activated charcoal. J. Agric. Food Chem., 56 (22), 10619-10624.
57. Chen, R.F. (1967) Removal of fatty acids from serum albumin by charcoal treatment. J. Biol. Chem., 242 (2), 173-181.
58. Nakano, N.I., Shimamori, Y., and Nakano, M. (1983) Activated carbon beads for the removal of highly albumin-bound species. Anal. Biochem., 129 (1), 64-71.
59. Nikolaev, V.G., Sarnatskaya, V.V., Sigal, U.L., Klevtsov, V.N., Makhorin, K.E., and Yushko, L.A. (1991) High porosity activated carbons for bilirubin removal. Int. J. Artif. Organs, 14, 179-185.
60. Weaver, J., Husson, S.M., Murphy, L., and Wickramasinghe, S.R. (2013) Anion exchange membrane adsorbers for flowthrough polishing steps: Part I. Clearance of minute virus of mice. Biotechnol. Bioeng., 110 (2), 491-499.
61. Weaver, J., Husson, S.M., Murphy, L., and Wickramasinghe, S.R. (2013) Anion exchange membrane adsorbers for flowthrough polishing steps: Part II. Virus, host cell protein, DNA clearance, and antibody recovery. Biotechnol. Bioeng., 110 (2), 500-510.
62. Riordan, W.T., Heilmann, S.M., Brorson, K., Seshadri, K., and Etzel, M.R. (2009) Salt tolerant membrane adsorbers for robust impurity clearance. Biotechnol. Prog., 25 (6), 1695-1702.
63. Riordan, W., Heilmann, S., Brorson, K., Seshadri, K., He, Y., and Etzel, M. (2009) Design of salt-tolerant membrane adsorbers for viral clearance. Biotechnol. Bioeng., 103 (5), 920-929.
64. Faber, R., Yujing, Y., and Gottschalk, U. (2009) Salt tolerant interaction chromatography for large-scale polishing with convective media. BioPharm. Int. Suppl., October, S11-S14.
65. Woo, M., Khan, N.Z., Royce, J., Mehta, U., Gagnon, B., Ramaswamy, S., Soice, N., Morelli, M., and Cheng, K.S. (2011) A novel primary amine-based anion exchange membrane adsorber. J. Chromatogr. A, 1218 (32), 5386-5392.
66. Joubert, M.K., Luo, Q., Nashed-Samuel, Y., Wypych, J., and Narhi, L.O. (2011) Classification and characterization of therapeutic antibody aggregates. J. Biol. Chem., 286 (28), 25118-25133.
67. Philo, J.S. (2009) A critical review of methods for size characterization of non-particulate protein aggregates. Curr. Pharm. Biotechnol., 10 (4), 359-372.
68. Yigzaw, Y., Hinckley, P., Hewig, A., and Vedantham, G. (2009) Ion exchange chromatography of proteins and clearance of aggregates. Curr. Pharm. Biotechnol., 10 (4), 421-426.
69. Kelley, B.D., Booth, J.E., Brown, P., Coffman, J., Godavarti, R., Iskra, T., Sun, S., Switzer, M.B., Vunnum, S., and Yu, T. (2011) Method of weak partitioning chromatography. US Pat. US8067182 B2 (November 29, 2011).
70. Liu, H.F., McCooey, B., Duarte, T., Myers, D.E., Hudson, T., Amanullah, A., van Reis, R., and Kelley, B.D. (2011) Exploration of overloaded cation exchange chromatography for monoclonal antibody purification. J. Chromatogr. A, 1218 (39), 6943-6952.
71. Brown, A., Bill, J., Tully, T., Radhamohan, A., and Dowd, C. (2010) Overloading ion-exchange membranes as a purification step for monoclonal antibodies. Biotechnol. Appl. Biochem., 56 (2), 59-70.
72. Mikhail Kozlov, W.C., Potty, A., Galipeau, K., Hamzik, J., Umana, J., and Peeck, L. (2013) Removal of protein aggregates from biopharmaceutical preparations in a flow-through mode. EMD Millipore Corporation. Patent WO2013138098A1.
73. Rathore, A.S., Latham, P., Levine, H., Curling, J., and Kaltenbrunner, O. (2004) Costing issues in the production of biopharmaceuticals. BioPharm. Int., 17, 46-146.
74. Sinclair, A. and Monge, M. (2010) Measuring manufacturing cost and its impact on organizations. BioProcess International, 8 (6), 10-15.
75. Felo, M., Christensen, B., and Higgins, J. (2013) Process cost and facility considerations in the selection of primary cell culture clarification technology. Biotechnol. Prog., 29 (5), 1239-1245.